Clinical Study

Reduction in Endometrioma Size with Three Months of Aromatase Inhibition and Progestin Add-Back

Table 1

Baseline demographics of study population.

Mean ± SDRange

Age/years32.4 ± 7.623–41
BMI/kg/m220.6 ± 2.316.7–23.2
Number of previous providers consulted for pain2.3 ± 1.31–4
Time since onset of symptoms/years8.2 ± 8.41–22
Mean baseline endometrioma diameter/cm4.6 ± 1.61.7–7.4
Mean baseline endometrioma volume/cm360.1 ± 58.72.6–212.2